Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Authors:
Open Access
- 30 September 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 52 (5) , 826-836
Abstract
Objectives: Pharmacokinetically enhanced co-amoxiclav 2000/125 mg was designed to achieve high serum concentrations of amoxicillin over the 12 h dosing interval to eradicate Streptococcus pneumoniae with amoxicillin MICs of at least 4 mg/L. Methods: This randomized, double-blind, double-dummy, multicentre study compared the efficacy and safety of oral co-amoxiclav 2000/125 mg twice daily versus co-amoxiclav 875/125 mg three times daily, for 7 or 10 days, in the treatment of community-acquired pneumonia (CAP). Results: The per-protocol (PP) population at follow-up (Days 18–39) comprised 114 patients receiving co-amoxiclav 2000/125 mg and 116 receiving co-amoxiclav 875/125 mg. Clinical success at follow-up (primary efficacy endpoint) in the clinical PP population was 94.7% (108/114) for co-amoxiclav 2000/125 mg versus 88.8% (103/116) for co-amoxiclav 875/125 mg [treatment difference (TD) = 5.9%, 95% CI: 1.1, 13.0]. Bacteriological success in the bacteriology PP population at follow-up was 85.0% (17/20) for co-amoxiclav 2000/125 mg versus 77.3% (17/22) for co-amoxiclav 875/125 mg (TD = 7.7%, 95% CI: 15.8, 31.2). Penicillin-resistant S. pneumoniae (PRSP) were isolated in three patients (including two with bacteraemia) in the co-amoxiclav 2000/125 mg group (amoxicillin MICs 8 mg/L, penicillin MICs 4 mg/L) and one in the comparator group; all were clinical and bacteriological successes. Co-amoxiclav 2000/125 mg and co-amoxiclav 875/125 mg were associated with adverse events leading to withdrawal in 6.3% and 6.2% of patients, respectively. Conclusions: Co-amoxiclav 2000/125 mg twice daily was at least as effective clinically as co-amoxiclav 875/125 mg three times daily in the treatment of CAP. Although few patients in this study had PRSP infection, 3/3 were successfully treated with co-amoxiclav 2000/125 mg.Keywords
This publication has 11 references indexed in Scilit:
- The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agentsJournal of Antimicrobial Chemotherapy, 2003
- The efficacy and safety of oral pharmacokinetically enhanced amoxycillin–clavulanate 2000/125 mg, twice daily, versus oral amoxycillin–clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adultsInternational Journal of Antimicrobial Agents, 2002
- Treatment of drug-resistant pneumococcal pneumoniaThe Lancet Infectious Diseases, 2002
- Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes Isolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in SpainAntimicrobial Agents and Chemotherapy, 2001
- Prevalence of Antimicrobial Resistance in Streptococcus pneumoniae Circulating in Italy: Results of the Italian Epidemiological Observatory Survey (1997-1999)Microbial Drug Resistance, 2001
- Re-evaluating current antibiotic therapyRespiratory Medicine, 2001
- Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997)Journal of Antimicrobial Chemotherapy, 2000
- ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory SocietyEuropean Respiratory Journal, 1998
- Practical Considerations and Guidelines for the Management of Community-Acquired PneumoniaDrugs, 1998
- Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance studyAntimicrobial Agents and Chemotherapy, 1996